Banner Bank Earns 2025 ‘Great Place to Work' Certification
WALLA WALLA, Wash.--(BUSINESS WIRE)--The Banner Bank leadership team is pleased to share the Bank was just certified by Great Place to Work®, a global research firm specializing in workplace culture and employee experience. The coveted worldwide certification is based entirely on what employees report about their workplace experience—specifically, how consistently they experience a high-trust work environment.
'Being certified as a Great Place to Work is especially meaningful because it is based on the feedback of our employees who are the foundation of our company,' said Mark Grescovich, President and CEO. 'This prestigious recognition reflects our commitment to creating and sustaining an exceptional workplace culture.'
The opinions of Banner employees were gathered through an extensive survey hosted by the research firm earlier this year. The survey results showed 86 percent of employees rank Banner as a great place to work—almost 20 percent higher than the average U.S. company. Great Place to Work Certification™ is the most definitive 'employer-of-choice' recognition companies aspire to achieve. Every year more than 21,000 companies across 170 countries apply to get certified.
We are incredibly honored to receive this recognition, and we owe it to our amazing employees,' said Kayleen Kohler, Chief Human Resources and Diversity Officer. 'Their passion, dedication and feedback helped us earn this certification. We appreciate the effort of our leaders at every level who consistently create the right environment for our employees to thrive.'
According to Great Place to Work research, employees at certified workplaces are 93 percent more likely to look forward to coming to work, are twice as likely to be paid fairly, earn a fair share of the company's profits and receive a promotion. Job seekers are also 4.5 times more likely to find a great boss at a certified workplace. Visit the Best Places to Work website to learn more about Banner Bank's certification.
About Banner Bank
Banner Bank is a Washington-chartered commercial bank serving consumer and business clients in Washington, Oregon, California and Idaho. With more than $16.2 billion in assets, Banner Bank is part of Banner Corporation (NASDAQ: BANR). Visit Banner Bank at www.bannerbank.com.
About Great Place to Work®
As the global authority on workplace culture, Great Place to Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place to Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Essentia Organic Mattress Fourth of July Sale Is Here and It's a Dream for Wellness Sleep Seekers
BOCA RATON, Fla., June 27, 2025 /PRNewswire/ -- Essentia Organic Mattress, a pioneer in organic, wellness-focused sleep technology, is celebrating Independence Day with its most anticipated summer promotion. From June 27 through July 4, customers can enjoy 25% off sitewide during the Fourth of July Sale, including all organic mattresses, bedding, and accessories. Essentia mattresses are crafted with the brand's patented Beyond Latex™ organic foam, providing unparalleled pressure relief, optimal spinal alignment, and superior breathability. Unlike conventional mattresses, Essentia's designs are free from springs, petrochemicals, and harmful toxins. As the sole organic mattress engineered to boost recovery and optimize sleep cycles, Essentia continues to define excellence in clean, high-performance sleep. "Our core mission goes beyond simply being organic; it's about delivering tangible sleep performance," says Jack Dell'Accio, founder and CEO of Essentia. "This sale offers a fantastic opportunity to experience our most advanced mattresses at a significant discount." This year's sale coincides with Essentia's 20th anniversary and the availability of The Dave Asprey Upgrade by Essentia. Developed in collaboration with renowned biohacker Dave Asprey, this innovative enhancement builds upon Essentia's commitment to tackling electromagnetic fields (EMFs) in the sleep environment. Available for Essentia's acclaimed Classic REM5 Active and Dormeuse REM9 Active organic performance mattresses, this upgrade features next-generation EMF Protection Foam with informed quartz and a graphene-infused organic cotton cover, creating a system that actively optimizes recovery and defends the body at a cellular level. For added convenience, new models such as the Grateful Eight Organic Mattress and the Venti Double-Sided Organic Latex Mattress are eligible for HSA and FSA reimbursement. Qualified customers can also take advantage of 12-month 0% APR financing options available through Affirm, making premium sleep more accessible than ever. Beyond mattresses, the Fourth of July Sale extends to Essentia's full range of organic pillows, sheets, pet beds, and crib mattresses. Every product is meticulously handcrafted in Essentia's GOLS and GOTS certified organic factory, ensuring the highest standards of quality and sustainability. Discover more and shop the Fourth of July Sale at About Essentia Organic Mattress: Essentia Organic Mattress is the pioneer behind the world's only Beyond Latex™ organic foam mattress, dedicated to delivering a superior sleep experience that goes beyond comfort. Our patented, non-toxic, and certified organic technology is scientifically designed to extend Deep and REM Sleep cycles by 20% to 60%, ensuring you wake up revitalized and ready to seize the day. As an eco-luxury brand, Essentia is committed to eliminating harmful toxins, allergens, and off-gasses commonly found in synthetic mattresses, offering a clean and safe sleep environment that supports your health and the planet. Our vegan, cruelty-free products are celebrated by professional athletes, health experts, and eco-conscious consumers who refuse to compromise on quality or sustainability. At Essentia, we pour our energy into creating the most advanced sleep solutions, so you can pour yours into living your most vibrant life. Discover the Essentia difference and experience sleep like never before. To learn more, visit View original content to download multimedia: SOURCE Essentia Organic Mattress Sign in to access your portfolio
Miami Herald
2 hours ago
- Miami Herald
Greenwich LifeSciences Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / June 27, 2025 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (Nasdaq:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 28, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interview in its entirety at: In an exclusive previously recorded interview, Snehal Patel, CEO of Greenwich LifeSciences, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the Company's mission to prevent breast cancer recurrences through GLSI-100, a novel breast cancer vaccine immunotherapy combining the HER2-derived GP2 peptide with GM-CSF. Patel highlights the promising results from a prior Phase II trial showing no metastatic recurrences in immunized patients and details the global expansion of the ongoing Phase III FLAMINGO-01 trial, now active at more than 120 sites across the U.S. and Europe. He also outlines the Company's strategy to accelerate commercialization through advanced manufacturing readiness and strong academic partnerships, positioning GLSI-100 as a potential game-changer in the HER2-positive breast cancer treatment landscape. GLSI is a client of RedChip Companies. Please read our full disclosure at About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc.
Associated Press
3 hours ago
- Associated Press
Ainnocence Launches BioSynthAI Platform for AI-Driven Synthetic Biology Product Discovery
'We are committed to advancing synthetic biology through the power of AI... BioSynthAI™'s launch is a major milestone in our mission to drive innovation for a more sustainable and healthier world.'— Dr. Lurong Pan MOUNTAIN VIEW, CA, UNITED STATES, June 27, 2025 / / -- Ainnocence, a next-generation biotech company specializing in AI-driven design, today announced the launch of its BioSynthAI™ platform, an advanced artificial intelligence solution for product discovery in the synthetic biology field. BioSynthAI™ leverages cutting-edge AI algorithms to optimize protein and enzyme activity through in-silico design, aiming to dramatically accelerate innovation across biopharmaceuticals and sustainable biotechnology. The launch comes at a time of rapid growth in synthetic biology – the global market was valued at $16.9 billion in 2024 and is projected to reach nearly $168 billion by 2035 ( ) – underscoring the strong demand for AI-driven solutions like BioSynthAI™. BioSynthAI™ is designed to streamline each stage of the synthetic biology development cycle. By integrating multi-omics data (genomic, proteomic, metabolomic, etc.) with expert biological models, the platform can design, simulate, and optimize biological systems significantly faster than traditional methods. Industry experts have suggested that intensive application of AI and automation could accelerate synthetic biology R&D timelines by as much as 20-fold, shrinking development cycles from a decade to mere months ( ). BioSynthAI™ realizes this potential by delivering optimized genetic designs and strain improvements in as little as a few hours, with end-to-end project turnarounds ranging from hours to two weeks. This represents a drastic reduction in time compared to conventional wet-lab experimentation, enabling researchers and companies to go from concept to prototype with unprecedented speed. Key Application Areas BioSynthAI™ is poised to drive breakthroughs across multiple sectors of synthetic biology. Key application areas include: • Green Biopharmaceuticals: Designing and optimizing therapeutic proteins and vaccines with environmentally sustainable processes. • Industrial Enzyme Development: Engineering high-efficiency enzymes for manufacturing, food processing, and other industrial applications. • Biofuel Production: Enhancing metabolic pathways in microbes to produce renewable biofuels (such as ethanol, biodiesel, or jet fuel) with higher yields and lower costs. • Biomaterial Synthesis: Creating novel biomaterials and bio-based chemicals (e.g. bioplastics, biofibers) as sustainable alternatives to petrochemical products. Core BioSynthAI™ Modules The BioSynthAI™ platform comprises four core modules, each addressing a critical step in the synthetic biology pipeline: • Gene Design Optimization: Uses AI-driven generative design to create and refine gene sequences or metabolic pathways for target molecules. This module explores billions of DNA or protein sequence variants to maximize performance traits such as enzyme activity, stability, and yield. • Strain Screening & Evolution: Leverages machine learning to predict the best-performing microbial strains and simulate directed evolution. It rapidly screens virtual strain variations and identifies optimal candidates for producing the desired product, significantly reducing the need for exhaustive lab trials. • Bioprocess Control: Employs artificial intelligence and automation to monitor and optimize bioprocess conditions in real time. From fermentation parameters to nutrient feed rates, this module adjusts process variables to ensure maximal efficiency and consistency in production. • Intelligent Production Integration: Connects the R&D pipeline with manufacturing, using AI to translate lab-scale successes into industrial-scale production. This module integrates data from pilot runs and manufacturing systems, enabling seamless scale-up and tech transfer for commercial bioproduction. Platform Strengths and Innovations BioSynthAI™'s strength lies in its comprehensive, end-to-end approach to synthetic biology innovation. Notable features and innovations of the platform include: • Multi-Omics Data Integration: The platform combines insights from genomics, transcriptomics, proteomics, metabolomics, and other omics data. This holistic view allows the AI to consider complex biological interactions and regulatory networks, leading to more accurate predictions and robust designs. • Synthetic Biology Expert Models: BioSynthAIT™ is built upon models trained on vast datasets and expert knowledge in synthetic biology and bioengineering. These domain-specific AI models incorporate known biochemical pathways, enzyme structures, and genetic design principles, giving the system a 'knowledge base' of what typically works in biological systems. • Experimental Data Validation Loop: Ainnocence has embedded a continuous validation mechanism in BioSynthAI™. Predicted designs (genes, enzymes, or strains) are experimentally synthesized and tested in Ainnocence's labs or partner facilities. The results are fed back into the AI models, allowing the platform to learn from real-world data and improving its predictive accuracy over time. • Rapid Project Turnaround: The platform is optimized for speed. Thanks to cloud computing and algorithmic efficiency, BioSynthAI™ can analyze and evaluate billions of possibilities within hours. In practice, Ainnocence offers deliverables from initial design to validated prototype in as fast as a few hours up to about two weeks, depending on project complexity. This rapid turnaround empowers companies to seize market opportunities and iterate quickly on ideas that would otherwise take months or years. 'At Ainnocence, we are committed to advancing synthetic biology through the power of AI,' said Dr. Lurong Pan, Founder and CEO of Ainnocence. 'BioSynthAI™ embodies that commitment by dramatically accelerating the product discovery process for our partners. By harnessing multi-omics data and our expert AI models, we can optimize enzymes, pathways, and entire organisms with unprecedented speed and precision. Our goal is to enable researchers and companies to tackle complex biological challenges – from developing greener pharmaceuticals to creating sustainable biofuels – faster and more efficiently than ever before. BioSynthAI™'s launch is a major milestone in our mission to drive innovation for a more sustainable and healthier world.' About Ainnocence Ainnocence is a California-based biotechnology company at the forefront of AI-driven design for drug discovery and synthetic biology. Founded in 2021, Ainnocence's radical AI platform is designed to minimize R&D risks and costs by up to 80%, and it boasts a computational capacity to screen up to 10 billion protein sequences or chemical compounds within hours ( ). By dramatically reducing discovery times while maintaining high success rates, Ainnocence empowers pharmaceutical, biotech, and industrial partners to pursue ambitious 'moonshot' projects. The company's AI technology has been used to accelerate the discovery of life-saving therapies and sustainable biomolecules, exemplifying Ainnocence's vision of AI as a catalyst for innovation in healthcare and environmental sustainability. For more information about BioSynthAI™ and Ainnocence's services in synthetic biology, please visit or contact [email protected]. Lurong Pan, PhD Ainnocence Inc +1 205-249-7424 [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
